日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Consensus and controversy in advanced urologic cancers: Insights from the Advanced Urologic Cancer Consensus Conference (AUC3) 2025

晚期泌尿系统癌症的共识与争议:来自2025年晚期泌尿系统癌症共识会议(AUC3)的启示

Jang, Albert; Zakharia, Yousef; Barata, Pedro C

Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer

非肌层浸润性膀胱癌免疫疗法的最新进展

Grier, Abby L; Zhong, Jeffrey Y; Basourakos, Spyridon; Calaway, Adam; Singh, Parminder; Zakharia, Yousef; Lucien, Fabrice; Karnes, R Jeffrey; Sharma, Vidit; Shah, Paras; Costello, Brian A; Pagliaro, Lance C; Orme, Jacob J; Brown, Jason R; Jang, Albert

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

RP1联合Nivolumab治疗晚期抗PD-1治疗失败的黑色素瘤(IGNYTE)

Wong, Michael K; Milhem, Mohammed M; Sacco, Joseph J; Michels, Judith; In, Gino K; Muñoz Couselo, Eva; Schadendorf, Dirk; Beasley, Georgia M; Niu, Jiaxin; Chmielowski, Bartosz; Wise-Draper, Trisha M; Bowles, Tawnya Lynn; Tsai, Katy K; Lebbé, Céleste; Gaudy-Marqueste, Caroline; Middleton, Mark R; Skolariki, Aglaia; Samson, Adel; Chesney, Jason A; VanderWalde, Ari M; Zakharia, Yousef; Harrington, Kevin J; Appleton, Elizabeth; Bommareddy, Praveen K; Zhu, Junhong; Viana, Marcus; Hou, Jeannie W; Coffin, Robert S; Robert, Caroline

Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape

生殖系全外显子组测序揭示了FOXP3相关基因变异与泌尿系统癌症易感性相关,并与免疫逃逸有关。

Feng, Bing-Jian; Kohlmann, Wendy; Nix, David A; Atkinson, Aaron; Boucher, Kenneth M; Carroll, Courtney; Stubben, Chris J; Kolesar, Jill; Singer, Eric A; Riedlinger, Gregory; Edge, Stephen; Sahu, Kamal Kant; Churchman, Michelle; Graham, Laura; Salhia, Bodour; Sanchez, Alejandro; Zakharia, Yousef; Schneider, Bryan P; Jain, Rohit; Byrne, Lindsey; Moskaluk, Christopher A; Nepple, Kenneth; Shabsigh, Ahmad; Chahoud, Jad; Cairns, Bradley R; Gupta, Sumati

Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer

VWA8、OSBPL6 和 ADAMTS9-AS2 基因单倍型与接受免疫检查点抑制剂治疗的癌症患者的免疫相关不良反应有关。

Raj, Prithvi; Liu, Jialiang; Zhu, Chengsong; Arana, Carlos; J Fattah, Farjana; Mu-Mosley, Hong; Switzer, Benjamin; Park, Jason Y; von Itzstein, Mitchell S; Wakeland, Edward K; Puzanov, Igor; Zakharia, Yousef; Daniels, Gregory A; Shaheen, Montaser F; Xie, Yang; SoRelle, Jeffrey A; Gerber, David E

Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma.

高剂量硒代-L-蛋氨酸联合阿昔替尼治疗既往接受过治疗的转移性透明细胞肾细胞癌患者的 I 期临床试验

Zakharia Yousef, Reis Ryan J, Kroll Matthew R, Rataan Aseel O, Manchkanti Srija, Rahim Bilal, Garje Rohan, Swami Umang, Mott Sarah L, Zamba K D, Sieren Jessica C, Salem Aliasger K, Rustum Youcef

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma

Brentuximab Vedotin 与 Pembrolizumab 联合治疗 PD-1 治疗的转移性非小细胞肺癌和转移性皮肤黑色素瘤的 II 期开放标签试验

Sylvia M Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina, Amanda Gillespie-Twardy, Inderjit Mehmi, Sunandana Chandra, Graham Watson, Patrick Ward, Marya Chaney, Hailing Lu, Jason Berndt, Brian P O'Connor, Kapil Rathi, Eeman Shaikh, Charles Lance Cowey3

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

前列腺癌中自然杀伤细胞浸润预示着患者预后改善

Zorko, Nicholas A; Makovec, Allison; Elliott, Andrew; Kellen, Samuel; Lozada, John R; Arafa, Ali T; Felices, Martin; Shackelford, Madison; Barata, Pedro; Zakharia, Yousef; Narayan, Vivek; Stein, Mark N; Zarrabi, Kevin K; Patnaik, Akash; Bilen, Mehmet A; Radovich, Milan; Sledge, George; El-Deiry, Wafik S; Heath, Elisabeth I; Hoon, Dave S B; Nabhan, Chadi; Miller, Jeffrey S; Hwang, Justin H; Antonarakis, Emmanuel S

Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes

更正:前列腺癌中自然杀伤细胞浸润预示着患者预后改善

Zorko, Nicholas A; Makovec, Allison; Elliott, Andrew; Kellen, Samuel; Lozada, John R; Arafa, Ali T; Felices, Martin; Shackelford, Madison; Barata, Pedro; Zakharia, Yousef; Narayan, Vivek; Stein, Mark N; Zarrabi, Kevin K; Patnaik, Akash; Bilen, Mehmet A; Radovich, Milan; Sledge, George; El-Deiry, Wafik S; Heath, Elisabeth I; Hoon, Dave S B; Nabhan, Chadi; Miller, Jeffrey S; Hwang, Justin H; Antonarakis, Emmanuel S

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

在程序性死亡受体1阻断耐药的黑色素瘤患者中,瘤内注射维杜托利莫德作为单药治疗或与帕博利珠单抗联合治疗:一项1b期研究的最终分析

Milhem, Mohammed M; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth I; Medina, Theresa; Daud, Adil; Ribas, Antoni; Chmielowski, Bartosz; Niu, Jiaxin; Gibney, Geoffrey T; Margolin, Kim; Olszanski, Anthony J; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Zhao, Luping; Kelley, Heather; Liu, Hong; Kumar, Sujatha; Bobilev, Dmitri; Krieg, Arthur M; Wooldridge, James E; Kirkwood, John M